Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
33
0

Year Published

2015
2015
2021
2021

Publication Types

Select...
6
3
1

Relationship

0
10

Authors

Journals

citations
Cited by 51 publications
(33 citation statements)
references
References 106 publications
0
33
0
Order By: Relevance
“…The exception is ibudilast, which is currently in a Phase 1 clinical trial for alcohol use disorders (ClinicalTrials.gov identifier: NCT02025998 [Ray, Roche, Heinzerling, & Shoptaw, 2014]), as well as in Phase 2 clinical trials for methamphetamine dependence (NCT01860807) and oxycodone abuse (NCT01740414). Multiple clinical trials have been initiated for the use of PDE inhibitors to treat cognitive deficits in neurodegenerative diseases, depression, and schizophrenia (Wang et al, 2015), including the PDE1 inhibitor vinpocetine, which recently completed Phase 1 of a clinical trial for improvement of cognition in epilepsy (NCT02011971).…”
Section: Translational Potential Of Pde Inhibitorsmentioning
confidence: 99%
“…The exception is ibudilast, which is currently in a Phase 1 clinical trial for alcohol use disorders (ClinicalTrials.gov identifier: NCT02025998 [Ray, Roche, Heinzerling, & Shoptaw, 2014]), as well as in Phase 2 clinical trials for methamphetamine dependence (NCT01860807) and oxycodone abuse (NCT01740414). Multiple clinical trials have been initiated for the use of PDE inhibitors to treat cognitive deficits in neurodegenerative diseases, depression, and schizophrenia (Wang et al, 2015), including the PDE1 inhibitor vinpocetine, which recently completed Phase 1 of a clinical trial for improvement of cognition in epilepsy (NCT02011971).…”
Section: Translational Potential Of Pde Inhibitorsmentioning
confidence: 99%
“…In animal models, inflammatory factors are associated with impulsive behavioral deficits (Morganti et al, 2015;. Recent research in psychiatry has also identified changes in neuroinflammation associated with abuse of a variety of substances, including psychostimulants (Dhillon et al, 2008;Fox et al, 2012;Najjar et al, 2013;Ray et al, 2014;Rodrigues et al, 2014). However, similar to aspects of the dopamine hypothesis of drug dependence, it is unclear whether these changes precede addiction, arise as a consequence thereof, or represent an interaction of these two alternatives.…”
Section: Introductionmentioning
confidence: 99%
“…Microglial activation, particularly the TLR4-mediated cascade, is a novel and promising target for neuropharmacological interventions (184, 185). In addition, prebiotic and/or probiotic supplements are receiving attention as an adjunctive therapy in HIV infection and AUD.…”
Section: Discussionmentioning
confidence: 99%